QuidelOrtho Corporation (QDEL) saw its stock surge 5.96% in after-hours trading on Wednesday, following the release of its third-quarter earnings report that surpassed analyst expectations. The in vitro diagnostics firm delivered robust financial results and provided an optimistic full-year outlook, despite ongoing challenges in the post-pandemic market.

The company reported third-quarter adjusted earnings per share of $0.80, significantly beating the consensus estimate of $0.46. Revenue for the quarter came in at $699.9 million, outperforming analyst expectations of $664.96 million. While this represents a 4% decrease from the prior year due to lower COVID-19 and Donor Screening revenue, the company's non-respiratory revenue grew by 5% as reported, demonstrating strength in its core business segments.

QuidelOrtho's President and CEO, Douglas Bryant, highlighted the company's successful cost-saving initiatives, which led to decreased operating expenses and an improved adjusted EBITDA margin of 25%, up 180 basis points from the previous year. The company also completed a debt refinancing during the quarter, enhancing its financial flexibility. Looking ahead, QuidelOrtho provided a positive outlook for the full year 2025, projecting revenue between $2.68 billion and $2.74 billion, and adjusted earnings per share in the range of $2.00 to $2.15. This forward-looking guidance, coupled with the company's strong performance in a challenging environment, likely contributed to investor enthusiasm and the subsequent after-hours stock price increase.